@article{94a3c1607e2e446a8b52a6b6dc9d219f,
title = "Response to ''To switch or not to switch': the missing piece in the puzzle of biosimilar literature?' by Scherlinger et al",
keywords = "Antirheumatic Agents, Biosimilar Pharmaceuticals, Etanercept, Humans, Registries, Treatment Outcome, DMARDs (biologic), disease activity, outcomes research, anti-TNF",
author = "Bente Glintborg and Loft, \{Anne Gitte\} and Emina Omerovic and Oliver Hendricks and Asta Linauskas and Jakob Espesen and Kamilla Danebod and Jensen, \{Dorte Vendelbo\} and Henrik Nordin and Dalgaard, \{Emil Barner\} and Stavros Chrysidis and Salome Kristensen and Raun, \{Johnny Lillelund\} and Hanne Lindegaard and Natalia Manilo and Jakobsen, \{Susanne H{\o}jmark\} and Hansen, \{Inger Marie Jensen\} and Pedersen, \{Dorte Dalsgaard\} and S{\o}rensen, \{Inge Juul\} and Andersen, \{Lis Smedegaard\} and Jolanta Grydeh{\o}j and Frank Mehnert and Krogh, \{Niels Steen\} and \{Lund Hetland\}, Merete",
note = "COPECARE",
year = "2020",
doi = "10.1136/annrheumdis-2018-214952",
language = "English",
volume = "79",
pages = "E37--E37",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "Elsevier BV",
number = "4",
}